GlassScriptPhysician profile
Kenny B Carter
NPI 1043307804
$13,343.45
in general payments reported to CMS, 2019-2025
30 companies · $943 in 2025
The $943 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,832 · 2020: $726 · 2021: $927 · 2022: $554 · 2023: $1,507 · 2024: $5,854 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,586 · Food and Beverage: $2,403 · Debt Forgiveness: $1,001 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,585.74 |
| Food and Beverage | $2,402.72 |
| Debt Forgiveness | $1,000.60 |
| Travel and Lodging | $314.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lazurite INC. | $4,585.74 | 2024 | |
| Intersect Ent, INC. | $2,819.37 | 2019-2021 | |
| Stryker Corporation | $1,324.66 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Xpress Loprofile |
| Photonicare INC | $1,000.60 | 2024 | Otosight Middle Ear Scope |
| Aerin Medical INC. | $799.35 | 2023-2024 | |
| Optinose US, INC. | $579.49 | 2019-2025 | |
| Genzyme Corporation | $358.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $336.20 | 2021-2025 | Dupixent |
| Medtronic, INC. | $256.07 | 2023-2025 | Stealthstation S8 Platform, Novapak, Bizact |
| Alk-Abello, INC | $234.28 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Glaxosmithkline, LLC. | $164.58 | 2021-2025 | Nucala |
| Abbvie INC. | $112.19 | 2020 | |
| Genentech, INC. | $109.91 | 2019 | |
| Sage Therapeutics, LLC | $102.80 | 2022 | |
| Acclarent, INC | $81.65 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $79.78 | 2019-2020 | |
| Phadia US INC. | $73.76 | 2022-2025 | Immunocap |
| Inspire Medical Systems, INC. | $56.89 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $42.75 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $26.93 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $25.26 | 2025 | Tezspire |
| Amgen INC. | $22.55 | 2025 | Tezspire |
| Integra Lifesciences Corporation | $20.98 | 2023 | Integra, Instruments-Orthopedic, Microfrance |
| Novartis Pharmaceuticals Corporation | $18.70 | 2021 | |
| Smith+Nephew, INC. | $17.22 | 2023 | Tula |
| Hikma Pharmaceuticals USA | $15.84 | 2022 | |
| Itamar Medical INC | $15.78 | 2021 | |
| Spirair, INC. | $14.61 | 2025 | |
| Covidien LP | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.